Warther Private Wealth LLC Purchases 392 Shares of Johnson & Johnson (NYSE:JNJ)

Posted by Defense World Staff on May 2nd, 2023

Warther Private Wealth LLC increased its position in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 3.2% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 12,765 shares of the company’s stock after acquiring an additional 392 shares during the period. Johnson & Johnson comprises about 1.7% of Warther Private Wealth LLC’s portfolio, making the stock its 21st biggest position. Warther Private Wealth LLC’s holdings in Johnson & Johnson were worth $2,255,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Nordwand Advisors LLC bought a new stake in shares of Johnson & Johnson in the 4th quarter valued at about $785,273,000. Edmp Inc. grew its position in shares of Johnson & Johnson by 17,222.9% in the 4th quarter. Edmp Inc. now owns 3,223,265 shares of the company’s stock valued at $18,247,000 after buying an additional 3,204,658 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Johnson & Johnson by 1.2% in the 3rd quarter. Vanguard Group Inc. now owns 245,340,875 shares of the company’s stock valued at $40,078,885,000 after buying an additional 2,815,655 shares during the last quarter. GQG Partners LLC grew its position in shares of Johnson & Johnson by 64.4% in the 1st quarter. GQG Partners LLC now owns 6,501,761 shares of the company’s stock valued at $1,151,931,000 after buying an additional 2,547,378 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership boosted its position in shares of Johnson & Johnson by 37.2% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 6,653,610 shares of the company’s stock valued at $1,179,219,000 after purchasing an additional 1,805,632 shares in the last quarter. Institutional investors own 67.94% of the company’s stock.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $163.60 on Tuesday. Johnson & Johnson has a fifty-two week low of $150.11 and a fifty-two week high of $183.35. The stock has a fifty day moving average of $157.86 and a 200-day moving average of $167.04. The company has a debt-to-equity ratio of 0.35, a quick ratio of 0.77 and a current ratio of 0.99. The stock has a market cap of $426.06 billion, a PE ratio of 34.23, a price-to-earnings-growth ratio of 2.78 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ – Get Rating) last posted its earnings results on Tuesday, April 18th. The company reported $2.68 EPS for the quarter, topping the consensus estimate of $2.51 by $0.17. Johnson & Johnson had a return on equity of 35.53% and a net margin of 13.22%. The business had revenue of $24.75 billion during the quarter, compared to analysts’ expectations of $23.61 billion. During the same period in the previous year, the business earned $2.67 earnings per share. The firm’s revenue was up 5.6% on a year-over-year basis. Equities research analysts anticipate that Johnson & Johnson will post 10.66 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 6th. Shareholders of record on Tuesday, May 23rd will be paid a dividend of $1.19 per share. The ex-dividend date of this dividend is Monday, May 22nd. This represents a $4.76 annualized dividend and a yield of 2.91%. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.13. Johnson & Johnson’s payout ratio is 94.56%.

Insiders Place Their Bets

In other Johnson & Johnson news, insider James D. Swanson sold 1,062 shares of Johnson & Johnson stock in a transaction dated Monday, March 6th. The stock was sold at an average price of $154.66, for a total transaction of $164,248.92. Following the completion of the sale, the insider now owns 9,215 shares of the company’s stock, valued at $1,425,191.90. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 0.20% of the company’s stock.

Analysts Set New Price Targets

JNJ has been the topic of several research analyst reports. Piper Sandler cut their target price on Johnson & Johnson from $55.00 to $52.00 in a research report on Monday, February 6th. Raymond James cut their target price on Johnson & Johnson from $185.00 to $181.00 and set an “outperform” rating on the stock in a research report on Wednesday, April 19th. SVB Leerink cut their target price on Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating on the stock in a research report on Friday, January 20th. UBS Group began coverage on Johnson & Johnson in a research note on Tuesday, March 28th. They set a “neutral” rating and a $164.00 price target on the stock. Finally, Atlantic Securities dropped their price target on Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 19th. Seven analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Johnson & Johnson has an average rating of “Moderate Buy” and an average price target of $173.00.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.